Johnson & Johnson at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

Johnson & Johnson takes part in 9 sessions at ACT 2026 in San Antonio. Its program centres on working with regulators and handling safety signals, including lessons learned from clinical holds. It also covers how to run an embryofetal development study, the immune risks of immunotherapies, and how pharma talks about the risks of PFAS, the forever chemicals.

Organization

ACT 2026 Attendance

Johnson & Johnson

New Brunswick, NJ

jnj.com

Pharmaceutical companies

Healthcare company whose Innovative Medicine arm, formerly Janssen, discovers, develops and markets prescription medicines.

Talk

Sun Nov 15
8:00am–8:05am

Part of Working with Global Regulators for Streamlined Nonclinical Development (CE4)

Introduction (CE4-1)

Regulatory

Session

Sun Nov 15
8:00am–11:30am

Working with Global Regulators for Streamlined Nonclinical Development (CE4)

Regulatory · with MEC Regulatory & Toxicology Consulting

8:00amIntroduction (CE4-1)Johnson & Johnson
8:05amTop Tips for Successful Nonclinical Regulatory Interaction (CE4-2)Charles River
8:30amIdeal Interaction During Drug Development: FDA Regulator's Perspective (CE4-3)U.S. Food and Drug Administration
9:00amIdeal Interaction During Drug Development: European Regulator's Perspective (CE4-4)Medicines Evaluation Board
10:00amSponsor Strategies for Successful Regulatory Agency Interactions (CE4-5)Lilly
10:30amInteractive Workshop: Practical Case Studies to Model Successful Regulatory Agency Interactions (CE4-6)MEC Regulatory & Toxicology Consulting

Talk

Sun Nov 15
9:00am–9:30am

Part of The ABCs of EFDs: A Modern Guide to Embryofetal Development Testing (CE3)

Conducting an EFD Study: The Essentials of Getting it Right (CE3-4)

DART

Talk

Sun Nov 15
3:00pm–3:20pm

Part of Immunotherapies and Collaborative Approaches to Immunosafety Assessment (CE6)

Effectively Evaluating, Understanding, and Communicating the Risky Behavior of Immunotherapies: The Complex and Diverse Role of a Project (Program) Toxicologist (CE6-5)

Immunotoxicology

Talk

Mon Nov 16
2:00pm–2:05pm

Part of Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06)

Introduction (S06-1)

Translational safety

Session

Mon Nov 16
2:00pm–5:00pm

Navigating Safety Signals and Clinical Holds: Lessons Learned from Nonclinical and Clinical Development (S06)

Translational safety

2:00pmIntroduction (S06-1)Johnson & Johnson
2:05pmDe-risking of Nonclinical Renal Safety Signals through Investigative Studies and Robust Clinical Monitoring (S06-2)Bristol Myers Squibb
2:40pmDILI Whodunnit: Responding to Drug Induced Liver Injury during TAK-994 Clinical Trials (S06-3)Takeda
3:45pmClinical Holds in the Development of Novel Genetic Medicines (S06-4)Bioepisteme
4:20pmProspective and Retrospective Risk Assessments of Safety Signals for a Rare Disease Biotherapeutic (S06-5)Amgen

Poster

Mon Nov 16
5:00pm–6:30pm

Validation of Organ-Specific Risk Estimates Derived from a Gene-Based Machine Learning Algorithm (P447)

Nelson Exhibit Ballroom · Poster P447

In silico and AI

Talk

Tue Nov 17
3:45pm–4:15pm

Part of The Evolving Landscape of Secondary Pharmacology and Off-Target Assessments in Pharmaceutical Development (S10)

Evolving Selectivity Assessment of Biologic Products with Cell-Based Protein Arrays and Derisking Strategies (S10-4)

Biologics and new modalities · Safety pharmacology

Talk

Wed Nov 18
2:25pm–2:45pm

Part of Invisible Ingredients, Critical Functions: The Risk Narrative around Excipients and PFAS (S17)

Risk Communication and Perception of Forever Chemicals and the Consequences for Pharma (S17-2)

Chemical risk assessment

Instantly find 20 buyers from Johnson & Johnson

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction